The Possibilities of Etiotropic Therapy for Influenza and ARVI with Taking into Account the Period of Hospitalization and the Risk of Developing Secondary Complications

Abstract

The article presents the results of a study of the clinical efficacy of Riamylovir (Triazavirinтм) in the treatment of adult patients with influenza and ARVI, taking into account the treatment time of patients from the onset of the disease and hospitalization in an infectious hospital. A statistically significant reduction in the time of observation of the symptoms of febrile-intoxication and catarrhal-respiratory syndromes in patients with influenza and ARVI was demonstrated both in the first 24-72 hours from the onset of the disease and in the 2nd week. The possibility of using Riamylovir in preventing the development of typical complications of ARVI has been shown.